Chemotherapy of metastatic carcinoma of the breast. A 4-drug regimen.
Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, methotrexate with leucoverin rescue) in 32 patients with metastatic carcinoma of the breast resulted in an overall response rate of 81 per cent (9/32 complete remission, 17/32 partial remission). No serious side effects were noted. Karnofsky performance index improved in 24/26 responders.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D012075:Remission, Spontaneous; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D008727:Methotrexate